Kelsey E. Larson

NF-κB in biology and targeted therapy: new insights and translational implications

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer

Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).